
CO39303
NCT03072238
JCP022
Ipatasertib Plus Abiraterone Plus Prednisone / Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone / Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer (IPATential150)
Status:
Closed to Accrual

III
Phase

1st
Line of Therapy

Advanced / Metastatic
Disease Stage

Biomarker(s)
N/A
Investigational
Product
Ipatasertib
AKT inhibitor (p.o.)
Treatment Arms
o Experimental: Ipatasertib + Abiraterone
o Active Comparator: Placebo + Abiraterone